Last week was an eventful week for Medibank Private Ltd (ASX: MPL) shareholders after it was revealed that the Australian Competition and Consumer Commission (ACCC) would take legal action against the private health insurer for misleading consumers.

The shares plunged more than 8% on the day of the announcement, but managed to claw back some of those losses throughout the rest of the week as investors took some time to absorb the news.

Despite last week’s setback, those shareholders who have held onto their shares since Medibank floated in December 2014 would be pretty happy. The shares have managed to increase by nearly 36% since listing, and as the chart below highlights, they have outperformed the broader market significantly.

Source: Google Finance

Source: Google Finance

The shares have performed well over the past 12 months in particular, and surprisingly, Medibank has been the second best performing large-cap stock during that period. Only gold miner, Newcrest Mining Limited (ASX: NCM), has put in a better performance.

Is Medibank a buy at $2.95 per share?

There are a number of reasons you could be bullish or bearish on Medibank right now.

Some of the reasons I would avoid Medibank include:

Sluggish Revenue Growth – Although Medibank recorded a strong rise in first half profits, the majority of the gains were made through cost savings. Revenue increased by only 4.6% with the company blaming slowing growth across the industry and higher churn rates. This sluggish revenue growth may become a serious problem in the future as there will come a time when cost saving measures no longer have an impact.

Higher customer premiums – The cost of healthcare is expected to significantly outpace the rate of inflation over the long term based purely on the dynamics of supply and demand. Inevitably, private health insurers will have to pass on these costs and this will put more pressure on premiums which could deter some people from having private health insurance. Worryingly, Medibank reported a 1.2% decline in policyholder growth in the first half and a significant increase in its customer lapse rate.

Valuation – Medibank shares are currently trading on a price-to-earnings ratio of around 21. This is not particularly cheap unless you are confident the company will continue to strip out costs in a bid to drive earnings growth.

Some of the reasons I would buy Medibank include:

Potential for further short-term cost savings – Medibank’s first half results showed the company made solid progress in reducing costs by clamping down on fraudulent claims and by negotiating better pricing with hospitals. The company is expected to improve operating margins by squeezing out further cost savings and this should help to support earnings in the short term.

Solid dividend – Investors can be pretty confident that Medibank will pay a solid dividend for the foreseeable future. At the current share price, investors can expect a fully franked dividend yield of around 3.6%.

Debt free balance sheet – Medibank has no long term debt on its balance sheet which means the company is in a fairly healthy financial position.

Foolish takeaway

Based on the points above, I would be inclined to avoid Medibank shares for the time being as the company is losing policyholders and cost savings can only go so far in the short term.

If the shares become cheaper or top line growth begins to accelerate, I would be far more confident in becoming a shareholder of the company.

Medibank might be popular with retail investors, but it's not at the top of my buy list just yet. Instead, investors would be better off considering one of these 'new breed' blue chips.

Forget BHP and Woolworths. These 3 "new breed" top blue chips for 2016 pay fully franked dividends and offer the very real prospect of significant capital appreciation. Click here to learn more.

The report is free! No credit card required.

HOT OFF THE PRESSES: Motley Fool’s #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our https://www.fool.com.au/financial-services-guide">Financial Services Guide (FSG) for more information.

Motley Fool contributor Christopher Georges has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.